Skip to main content

Table 2 Clinical characteristics of high-titer MOG-IgG seropositive patients with NMO (n = 3), HR-NMO (n = 7) and CIS (n = 2)

From: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

No./Sex/Age (y)

Diagnosis

MOG-IgG

titer

AQP4-IgG

titer

relapses

ON

myelitis

LETM

Cerebral MRI lesions

MOG -TCC

1/F/2

NMO

1:2,560

negative

2

yes

yes

yes

no

pos

2/F/39

NMO

1:160

1:1,280

4

yes

yes

yes

no

n.a

3/M/56

NMO

1:2,560

negative

2

yes

yes

yes

n.a

pos

4/F/28

HR-NMO (rON)

1:5,120

negative

2

yes

no

no

no

pos

5/M/13

HR-NMO (rON)

1:5,120

negative

3

yes

no

no

no

pos

6/F/48

HR-NMO (rON)

1:2,560

negative

16

yes

no

no

no

pos

7/F/46

HR-NMO (rON)

1:640

negative

3

yes

no

no

no

neg

8/M/32*

HR-NMO (rON)

1:640

negative

11

yes

no

no

no

neg

9/F/43

HR-NMO (LETM)

1:2,560

negative

1

no

yes

yes

no

pos

10/F/49*

HR-NMO (LETM)

1:640

negative

1

no

yes

yes

no

pos

11/F/5

CIS (ON)

1:5,120

negative

1

yes

no

no

no

pos

12/M/13

CIS (ON)

1:640

negative

1

yes

no

no

no

neg

  1. Abbreviations: No. = patient number, F = female, M = male, y = years, MRI = magnetic resonance image, NMO = Neuromyelitis optica, HR-NMO = High-risk NMO, rON = recurrent optic neuritis, ON = optic neuritis, LETM = longitudinally extensive transverse myelitis, CIS = clinically isolated syndrome, MOG-TCC = MOG-IgG dependent terminal complement complex, n.a = not available. * paired serum and CSF samples were available from patient 8 and 10. The corresponding CSF was found to be negative for AQP4-IgG as well as for MOG-IgG (CSF was analyzed undiluted and diluted 1:2 as previously described [48]).